Employees: 450
Size Mayne Pharma (MYX.AX) is an Australia Health Care company (Pharmaceuticals: Major) with a market value of $333M, the 304th largest of 317 Australia companies the cockpit tracks. Shares closed at A$6.06 on 18 Nov 2026.
Performance Over six months the shares gained 154.6%, against -20.4% for the median peer and +1.2% for the Australia market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +2.7%); the operating margin is -14.5% (peer median 3.0%).
Valuation It trades at 1.2× enterprise value to sales against a peer median of 2.8× (4th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 19.8 points below its cost of capital (8.7% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$384M | A$384M | A$408M | A$388M | A$184M |
| Revenue growth | — | -6% | +5% | +112% | — |
| Gross profit | A$190M | A$192M | A$186M | A$159M | A$26.8M |
| EBITDA | A$8.14M | A$29.8M | A$45.6M | -A$9.38M | -A$121M |
| Net income | A$24.5M | A$24.5M | -A$93.8M | -A$174M | -A$316M |
| Free cash flow | A$12.7M | A$12.7M | A$9.83M | -A$17.5M | -A$51.5M |
| Capital expenditure | A$3.32M | A$3.32M | A$27.8M | A$20.9M | A$220M |
| Total debt | n/a | A$43.2M | A$41.3M | A$38.8M | A$47.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MYX.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +138.6% | -6.1% | highest of 21 |
| 6-month return | +154.6% | -20.4% | highest of 21 |
| Distance from 52-week high | -0.2% | -35.7% | highest of 21 |
| Revenue growth (TTM) | -6.0% | +2.7% | 7th lowest of 20 |
| Operating margin | -14.5% | 3.0% | 6th lowest of 19 |
| EV / Sales | 1.2× | 2.8× | 4th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 19.0% | 8.6% | 4th most demanding of 13 |
| Growth delivered (Del g) | -0.9% | +4.8% | 5th lowest of 13 |
| Hurdle (Req g minus delivered) | +19.9 pp | +4.8 pp | 4th most demanding of 13 |
| ROIC minus cost of capital | -19.8 pp | -7.0 pp | 4th lowest of 18 |
| Net debt / EBITDA | -4.8× | -0.3× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | 1.2× | 19.0% | -0.9% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | 1.4× | 9.2% | +6.5% |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 4.8× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 2.4× | 38.3% | -3.2% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | 1.8× | -11.5% | +10.3% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | 7.4× | 14.3% | -14.0% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | 6.2× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | 21.4× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 1.8× | 6.1% | +62.1% |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | 1.1× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 3.1× | -16.8% | +5.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | 921.6× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | 1.9× | 8.0% | -11.3% |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | 3.4× | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | 5.6× | 27.5% | -6.4% |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | 1.1× | 3.6% | +3.1% |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | 13.0× | 44.3% | +26.7% |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | 2.1× | 14.0% | +7.3% |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 0.5× | 6.7% | +4.2% |